Bumetanide is FDA-approved for managing various edematous conditions secondary to cardiac failure or hepatic or renal disease, including nephrotic syndrome. It is a member of the loop diuretic class of drugs. This activity reviews bumetanide's indications, action, and contraindications as a valuable agent in treating and managing various edematous conditions secondary to cardiac failure or hepatic or renal disease. This activity will highlight the mechanism of action, adverse effects, and other key factors such as dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions pertinent for interprofessional team members in the treatment and care of patients with edematous conditions.

**Objectives:**
- Identify the mechanism of action of bumetanide.
- Describe the potential adverse effects of bumetanide.
- Review the appropriate monitoring of patients receiving bumetanide.
- Summarize interprofessional team strategies for improving care coordination and communication to advance bumetanide and improve outcomes.